Oppenheimer upgraded PMV Pharmaceuticals (PMVP) to Outperform from Perform with a $6 price target after the company reported Q3 results and provided a business update. The Phase 2 pivotal monotherapy trial for rezatapopt remains on track, with interim results anticipated mid-2025, notes the analyst, who cites the valuation discrepancy versus cash and the upcoming interim readout.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMVP: